A retrospective study of immune‐related toxicities in patients who treated with programmed cell death‐1 checkpoint inhibitors including pembrolizumab, nivolumab, and Atezolizumab
Latest Information Update: 10 Dec 2020
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- 10 Dec 2020 New trial record